1. Home
  2. ORMP vs IMNM Comparison

ORMP vs IMNM Comparison

Compare ORMP & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oramed Pharmaceuticals Inc.

ORMP

Oramed Pharmaceuticals Inc.

HOLD

Current Price

$4.13

Market Cap

197.6M

Sector

Health Care

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$18.01

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORMP
IMNM
Founded
2002
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
197.6M
2.5B
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
ORMP
IMNM
Price
$4.13
$18.01
Analyst Decision
Strong Buy
Analyst Count
0
17
Target Price
N/A
★ $35.19
AVG Volume (30 Days)
136.7K
★ 1.4M
Earning Date
11-12-2026
11-05-2026
Dividend Yield
★ 6.04%
N/A
EPS Growth
★ 412.50
51.40
EPS
★ 2.76
N/A
Revenue
$2,000,000.00
★ $6,941,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18,803.97
P/E Ratio
$1.50
★ N/A
Revenue Growth
★ 49.25
N/A
52 Week Low
$2.09
$14.64
52 Week High
$5.47
$30.06

Technical Indicators

Market Signals
Indicator
ORMP
IMNM
Relative Strength Index (RSI) 36.24 34.57
Support Level $3.91 $17.83
Resistance Level $4.22 $23.48
Average True Range (ATR) 0.16 0.99
MACD -0.02 -0.02
Stochastic Oscillator 35.04 30.57

Price Performance

Historical Comparison
ORMP
IMNM

About ORMP Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: